The Aflac Cancer & Blood Disorders Center of Children's Healthcare of Atlanta is hosting the 2025 Sickle Cell Transplant Advocacy & Research Alliance (STAR) Annual Meeting. We are honored to bring together hematologists and transplant physicians for this important 2-day event.
CONGRESS | #Tandem25@MunaQayed, @EmoryUniversity discussed the impact of #GvHD on leukemia-free survival. In this study, GvHD did not reduce relapse risk in #ALL or #AML, and severe aGvHD led to inferior OS.
https://t.co/7whprdsds2
In the midst of an extremely difficult period, Lamya and I are walking to help support our university and the communities it serves. #AUB4BeirutRun2024
Excited for a new phase of caring for children and a new #AtlBMT unit at @childrensatl Arthur M. Blank Hospital. Bittersweet goodbye to the Egleston campus.
@ATLPedsHemOnc
Important Reminder! 📣 Arthur M. Blank Hospital is opening its doors this Sunday, September 29, 2024. Thank you for your understanding as we transfer patients—please yield to ambulances near our hospitals. For more information, please visit: https://t.co/bkmBQ5nWqy.
🎙️Had a great convo with @ASamerAlHomsi1 regarding the novel PTCy + abatacept + short course tacrolimus (#CAST regimen) - a potential game changer in #GVHD prophylaxis and perhaps next evolution of #PTCyRules.
Also first time hosting @ASTCT Talks! I hope you enjoy!🙏
https://t.co/fL3figgWpW
A validated risk stratification that incorporates MAGIC biomarkers predicts long-term outcome in pediatric patients with acute #GVHD. Biomarker-based risk stratification can be used in clinical trials to develop methods for children who require treatment. https://t.co/TXqqVaNP73
I'm excited to share that the @Incyte Ingenuity Awards in GVHD is accepting applications! This program supports unique proposals, like mine, that address specific needs of the graft-versus-host disease (#GVHD) community. If you have an idea, apply today: https://t.co/UbThh3rmQs
#tandem24@ThePTCTC lymphoma risk in inborn errors of immunity great slides Dr. Shan Chandrakasan, when to think of IEI in lymphoma pts, basis, risk, presentation